AlphaYou
Overview
Smart money at a glance
Filings to Oct 13, 2026Net buying: insiders sold $0 and bought $24K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$24K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 12- Open
- $3.07
- 52-wk high
- $5.89
- High
- $3.25
- 52-wk low
- $2.66
- Low
- $3.07
- Prev close
- $3.07
- Mkt cap
- $56.7M
- Volume
- 22.7K
- Beta
- -0.01
- P/S
- 15.7x
- P/B
- 2.3x
- Profit margin
- +0.0%
- Op margin
- -1816.0%
- ROE
- -55.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ATHE filings
Are insiders buying or selling Alterity Therapeutics Ltd (ATHE) stock?
Net buying: insiders sold $0 and bought $24K of ATHE stock on the open market in the 90 days to Oct 13, 2026, according to SEC Form 4 filings. The largest was Marks, Peter Ashley (Director), who bought $24K. The latest filing was on Sep 8, 2026.
Which members of Congress have traded ATHE recently?
None. No member of Congress disclosed a ATHE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ATHE smart-money data?
This summary uses filings available on Oct 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
1 fund holds a position and insiders have been net buying.
What insiders are doing
Buys (1)
- MP
Marks Peter Ashley
$24K
bought
How top traders are positioned
No tracked top-trader positions in ATHE right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No reported figure for the latest quarter.
Company release linked above, where available
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 27, 2026 | Unavailable | - | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | $0.00 / -$0.67Alpha Vantage | +100.00% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 3, 2025 | $0.00 / -$0.11Alpha Vantage | +100.00% beat | Unavailable | Unavailable |
| Mar 31, 2023 | Jun 29, 2023 | Unavailable | - | Unavailable | Unavailable |
| Dec 31, 2022 | Feb 27, 2023 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2022 | Nov 30, 2022 | Unavailable | - | Unavailable | Unavailable |
| Jun 30, 2022 | Aug 30, 2022 | -$0.24 / -$0.24Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Mar 31, 2022 | Jun 29, 2022 | Unavailable | - | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
What the street expects next
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $57M
Valuation
- P/S15.71
- P/B2.27
Quality
- Operating margin-1816.0%
- ROE-55.0%
- ROA-34.1%
Growth
- Beta-0.01
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace